NZ708738A - Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity - Google Patents
Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activityInfo
- Publication number
- NZ708738A NZ708738A NZ708738A NZ70873813A NZ708738A NZ 708738 A NZ708738 A NZ 708738A NZ 708738 A NZ708738 A NZ 708738A NZ 70873813 A NZ70873813 A NZ 70873813A NZ 708738 A NZ708738 A NZ 708738A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compounds
- agonist activity
- beta2 adrenergic
- methyl
- adrenergic receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients. An exemplary compound of the invention is 2-(4-((((R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)-methyl)-2-methylphenoxy)ethyl 4-((3-((S)-phenyl((((R)-quinuclidin-3-yloxy)carbonyl)-amino)methyl)phenoxy)methyl)benzoate:
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195891 | 2012-12-06 | ||
| PCT/EP2013/075661 WO2014086924A1 (en) | 2012-12-06 | 2013-12-05 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ708738A true NZ708738A (en) | 2019-02-22 |
Family
ID=47323975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ708738A NZ708738A (en) | 2012-12-06 | 2013-12-05 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8987299B2 (en) |
| EP (2) | EP2928889B1 (en) |
| JP (1) | JP6421989B2 (en) |
| KR (2) | KR102156443B1 (en) |
| CN (1) | CN104822678B (en) |
| AR (1) | AR093825A1 (en) |
| AU (1) | AU2013354043C1 (en) |
| BR (1) | BR112015012730B1 (en) |
| CA (1) | CA2893626C (en) |
| CL (1) | CL2015001483A1 (en) |
| CO (1) | CO7400870A2 (en) |
| CY (2) | CY1120159T1 (en) |
| DK (2) | DK2928889T3 (en) |
| EA (1) | EA030552B1 (en) |
| ES (2) | ES2670686T3 (en) |
| GE (1) | GEP20186839B (en) |
| HK (1) | HK1212989A1 (en) |
| HR (2) | HRP20180915T1 (en) |
| HU (2) | HUE051394T2 (en) |
| IL (1) | IL239182B (en) |
| LT (2) | LT3345904T (en) |
| MA (1) | MA38147B1 (en) |
| MX (1) | MX369311B (en) |
| NZ (1) | NZ708738A (en) |
| PE (1) | PE20151216A1 (en) |
| PH (1) | PH12015501247A1 (en) |
| PL (2) | PL2928889T3 (en) |
| PT (2) | PT2928889T (en) |
| RS (2) | RS57232B1 (en) |
| SA (1) | SA515360514B1 (en) |
| SG (2) | SG10201704032RA (en) |
| SI (2) | SI2928889T1 (en) |
| TN (1) | TN2015000244A1 (en) |
| TR (1) | TR201808698T4 (en) |
| TW (1) | TWI637954B (en) |
| UA (1) | UA118181C2 (en) |
| WO (1) | WO2014086924A1 (en) |
| ZA (1) | ZA201503965B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20110083U1 (en) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | PLATE FOR THE CONSTRUCTION OF TRUCKS FOR AIRPLANES |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| AR093832A1 (en) * | 2012-12-06 | 2015-06-24 | Chiesi Farm Spa | COMPOUNDS WITH ANTAGONIST ACTIVITY OF THE MUSCARINIC RECEPTORS AND AGONIST ACTIVITY OF THE ADRENERGIC RECEIVER b2 |
| MA38147B1 (en) * | 2012-12-06 | 2018-09-28 | Chiesi Farm Spa | Compounds with muscarinic receptor antagonist activity and beta2 adrenergic receptor agonist |
| MA38260B1 (en) | 2012-12-18 | 2018-04-30 | Almirall Sa | Novel cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist activity and muscarinic m3 antagonist activity |
| TWI643853B (en) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES |
| TWI641373B (en) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES |
| TW201517906A (en) | 2013-07-25 | 2015-05-16 | Almirall Sa | Combinations comprising MABA compounds and corticosteroids |
| TW201617343A (en) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities |
| TWI703138B (en) | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| AR104828A1 (en) * | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | COMPOUNDS WITH ANTAGONIST ACTIVITY OF THE MUSCARINIC RECEIVERS AND AGONIST ACTIVITY OF THE ADRENERGIC RECEIVER b2 |
| TWI731891B (en) * | 2015-11-16 | 2021-07-01 | 義大利商吉斯藥品公司 | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
| EP3383867B1 (en) | 2015-12-03 | 2021-04-14 | Chiesi Farmaceutici S.p.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| WO2018011090A1 (en) | 2016-07-13 | 2018-01-18 | Chiesi Farmaceutici S.P.A. | Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| CA2994290C (en) | 2017-11-06 | 2024-01-23 | Entech Solution As | Method and stimulation sleeve for well completion in a subterranean wellbore |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2222128A (en) | 1937-01-29 | 1940-11-19 | Pure Oil Co | Preparation and separation of aromatic hydrocarbons |
| DE19921693A1 (en) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects |
| WO2004032921A1 (en) | 2002-10-11 | 2004-04-22 | Pfizer Limited | Indole derivatives as beta-2 agonists |
| PE20040950A1 (en) | 2003-02-14 | 2005-01-01 | Theravance Inc | BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS |
| CA2543858C (en) | 2003-11-21 | 2014-04-15 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| ATE369333T1 (en) | 2004-01-22 | 2007-08-15 | Pfizer | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| US7538141B2 (en) | 2004-03-23 | 2009-05-26 | Alan Daniel Brown | Compounds for the treatment of diseases |
| WO2005092840A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Formamide derivatives useful as adrenoceptor |
| ES2257152B1 (en) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS. |
| US7569586B2 (en) | 2004-08-16 | 2009-08-04 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| US7528253B2 (en) | 2004-08-16 | 2009-05-05 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| FR2898640B1 (en) | 2006-03-20 | 2008-04-25 | Siemens Vdo Automotive Sas | METHOD FOR TRANSMITTING INFORMATION RELATING TO THE OPERATION OF AN INTERNAL COMBUSTION ENGINE |
| EP2080523A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| DK3210981T3 (en) | 2009-04-23 | 2019-04-01 | Theravance Respiratory Co Llc | DIAMIDE COMPOUNDS WITH MUSCARINE RECEPTOR ANTAGONIST AND BETA-2 ADDRESSER RECEPTOR AGONIST ACTIVITY |
| WO2010126025A1 (en) * | 2009-04-30 | 2010-11-04 | 帝人ファーマ株式会社 | Quaternary ammonium salt compound |
| WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| PE20141614A1 (en) * | 2011-06-10 | 2014-11-20 | Chiesi Farma Spa | COMPOUNDS WITH ANTAGONISTIC ACTIVITY OF THE MUSCARINAL RECEPTORS AND AGONISTIC ACTIVITY OF THE BETA2 ADRENERGIC RECEPTOR |
| KR20180085068A (en) | 2011-06-10 | 2018-07-25 | 키에시 파르마슈티시 엣스. 피. 에이. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| AR093832A1 (en) * | 2012-12-06 | 2015-06-24 | Chiesi Farm Spa | COMPOUNDS WITH ANTAGONIST ACTIVITY OF THE MUSCARINIC RECEPTORS AND AGONIST ACTIVITY OF THE ADRENERGIC RECEIVER b2 |
| MA38147B1 (en) * | 2012-12-06 | 2018-09-28 | Chiesi Farm Spa | Compounds with muscarinic receptor antagonist activity and beta2 adrenergic receptor agonist |
-
2013
- 2013-12-05 MA MA38147A patent/MA38147B1/en unknown
- 2013-12-05 EP EP13811827.8A patent/EP2928889B1/en active Active
- 2013-12-05 GE GEAP201313845A patent/GEP20186839B/en unknown
- 2013-12-05 EP EP18156043.4A patent/EP3345904B1/en active Active
- 2013-12-05 AR ARP130104529A patent/AR093825A1/en unknown
- 2013-12-05 CN CN201380063365.2A patent/CN104822678B/en active Active
- 2013-12-05 SG SG10201704032RA patent/SG10201704032RA/en unknown
- 2013-12-05 AU AU2013354043A patent/AU2013354043C1/en active Active
- 2013-12-05 LT LTEP18156043.4T patent/LT3345904T/en unknown
- 2013-12-05 SI SI201330994T patent/SI2928889T1/en unknown
- 2013-12-05 ES ES13811827.8T patent/ES2670686T3/en active Active
- 2013-12-05 HU HUE18156043A patent/HUE051394T2/en unknown
- 2013-12-05 LT LTEP13811827.8T patent/LT2928889T/en unknown
- 2013-12-05 BR BR112015012730-4A patent/BR112015012730B1/en active IP Right Grant
- 2013-12-05 PL PL13811827T patent/PL2928889T3/en unknown
- 2013-12-05 DK DK13811827.8T patent/DK2928889T3/en active
- 2013-12-05 KR KR1020157014956A patent/KR102156443B1/en active IP Right Grant
- 2013-12-05 HU HUE13811827A patent/HUE037944T2/en unknown
- 2013-12-05 ES ES18156043T patent/ES2816210T3/en active Active
- 2013-12-05 JP JP2015546012A patent/JP6421989B2/en active Active
- 2013-12-05 PT PT138118278T patent/PT2928889T/en unknown
- 2013-12-05 RS RS20180529A patent/RS57232B1/en unknown
- 2013-12-05 UA UAA201505478A patent/UA118181C2/en unknown
- 2013-12-05 NZ NZ708738A patent/NZ708738A/en not_active IP Right Cessation
- 2013-12-05 PT PT181560434T patent/PT3345904T/en unknown
- 2013-12-05 SG SG11201504318UA patent/SG11201504318UA/en unknown
- 2013-12-05 PL PL18156043T patent/PL3345904T3/en unknown
- 2013-12-05 EA EA201590873A patent/EA030552B1/en unknown
- 2013-12-05 PE PE2015000738A patent/PE20151216A1/en active IP Right Grant
- 2013-12-05 KR KR1020207006181A patent/KR102240459B1/en active IP Right Grant
- 2013-12-05 TR TR2018/08698T patent/TR201808698T4/en unknown
- 2013-12-05 WO PCT/EP2013/075661 patent/WO2014086924A1/en active Application Filing
- 2013-12-05 RS RS20201150A patent/RS60864B1/en unknown
- 2013-12-05 TW TW102144561A patent/TWI637954B/en not_active IP Right Cessation
- 2013-12-05 DK DK18156043.4T patent/DK3345904T3/en active
- 2013-12-05 CA CA2893626A patent/CA2893626C/en active Active
- 2013-12-05 SI SI201331764T patent/SI3345904T1/en unknown
- 2013-12-05 MX MX2015006788A patent/MX369311B/en active IP Right Grant
- 2013-12-06 US US14/098,735 patent/US8987299B2/en active Active
-
2015
- 2015-01-23 US US14/603,926 patent/US9371318B2/en active Active
- 2015-06-02 CL CL2015001483A patent/CL2015001483A1/en unknown
- 2015-06-03 PH PH12015501247A patent/PH12015501247A1/en unknown
- 2015-06-03 IL IL239182A patent/IL239182B/en active IP Right Grant
- 2015-06-03 ZA ZA2015/03965A patent/ZA201503965B/en unknown
- 2015-06-03 CO CO15127118A patent/CO7400870A2/en unknown
- 2015-06-03 TN TNP2015000244A patent/TN2015000244A1/en unknown
- 2015-06-03 SA SA515360514A patent/SA515360514B1/en unknown
-
2016
- 2016-01-29 HK HK16101057.0A patent/HK1212989A1/en unknown
-
2018
- 2018-05-03 CY CY20181100469T patent/CY1120159T1/en unknown
- 2018-06-13 HR HRP20180915TT patent/HRP20180915T1/en unknown
-
2020
- 2020-09-09 HR HRP20201435TT patent/HRP20201435T1/en unknown
- 2020-09-28 CY CY20201100912T patent/CY1123365T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ708738A (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| SG195375A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| EP4268814A3 (en) | Pharmaceutical composition for the treatment of dry eye | |
| EP2917180A4 (en) | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient | |
| PH12017501424A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| WO2012147107A3 (en) | Novel & improved processes for preparing indoline derivatives and its pharmaceutical composition | |
| MX2014005635A (en) | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolin amide derivatives as orexin receptor antagonists. | |
| EA201170676A1 (en) | AGONISTS OF RECEPTOR MELANOCORTIN | |
| EA201390977A1 (en) | COMBINATION OF OPIOID RECEPTOR AGONIST AND OPIOID RECEPTOR ANTAGONIST FOR THE TREATMENT OF PARKINSON'S Disease | |
| MX342324B (en) | Otamixaban formulations with improved stability. | |
| MX2017015047A (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity. | |
| PE20130813A1 (en) | NEW ASSOCIATION BETWEEN 4- {3- [CIS-HEXAHYDROCYCLOPENTA [C] PIRROL-2 (1H) -IL] PROPOXI} BENZAMIDE AND AN ANTAGONIST OF NMDA RECEPTORS AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT | |
| PH12015501389A1 (en) | Pharmaceutical formulation of n- [5-[2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide | |
| TN2013000429A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| TH162209A (en) | A new type of cyclohexylamine derivative with the activity of beta2adrenergic and M3 muscarin. | |
| UA109581C2 (en) | COMPOUNDS WITH THE ACTIVITY OF MUSCARIN RECEPTORS ANGONISTS AND BET2 ADRENERGY RECEPTOR AGONISTS | |
| TH134757A (en) | Pharmaceutical constituents containing linagliptin and SGLT2 inhibitors and their use may be selected. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2020 BY COMPUTER PACKAGES INC Effective date: 20191119 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2021 BY COMPUTER PACKAGES INC Effective date: 20201118 |
|
| LAPS | Patent lapsed |